SpePharm Sells Japanese Rights for Savene(R) to Kissei Pharmaceutical Co., Ltd.
9/1/2011 10:08:01 AM
More...
|
BioAlliance Pharma Filed an Appeal to the French Supreme Court Contesting a Preliminary Procedural Decision on Jurisdiction in the Arbitration Against SpePharm and SpeBio
6/1/2011 12:53:45 PM
More...
|
The Paris Court Of Appeals Rejects the Appeals Lodged by BioAlliance Pharma In A Case Against SpePharm and Spebio BV, And Orders Bioalliance Pharma to Refund in Total €500K Of Legal Costs to the Two Companies
5/31/2011 2:40:03 PM
More...
|
SpePharm Announces the Acquisition of Savene(R) from TopoTarget A/S; 11 Million Euros New Round of Financing, and a Strategic Partnership with Paladin Labs Inc. (CC:PLB)
3/4/2010 6:55:53 AM
More...
|
Access Pharmaceuticals (ACCP) Announces Commercial Launch of MuGard(TM) in Norway by SpePharm
7/27/2009 9:05:01 AM
More...
|
Access Pharmaceuticals (ACCP) Announces Commercial Launch of MuGard(TM) in Greece by SpePharm
6/30/2009 8:25:36 AM
More...
|
Access Pharmaceuticals (ACCP) Announces the European Launch of MuGard(TM) by its European Partner, SpePharm
4/22/2009 8:50:33 AM
More...
|
SpePharm Announces the European Launches of Two New Products: MuGard(R) and Xerotin(R)
4/20/2009 10:08:12 AM
More...
|
SpePharm Announces a Claim in Excess of 35 Million Euros Against BioAlliance Pharma For Breaking up Their Joint-Venture
4/14/2009 6:57:48 AM
More...
|
SpePharm Initiates Legal Actions Against BioAlliance Pharma for Breaking Up Joint-Venture SpeBio
3/3/2009 10:44:49 AM
More...
|
|